Q32 Bio (QTTB) Consolidated Net Income (2017 - 2026)

Q32 Bio's Consolidated Net Income history runs 10 years deep, the most recent figure standing at -$16.1 million for Q1 2026.

• On a quarterly basis, Consolidated Net Income fell 45.83% year-over-year to -$16.1 million in Q1 2026; TTM through Mar 2026 was $24.8 million, a 142.45% increase from a year earlier, with the FY2025 full-year figure at $29.8 million, up 164.68% from the prior year.
• Consolidated Net Income retreated to -$16.1 million in Q1 2026 per QTTB's latest filing, from $57.7 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at $92.7 million in Q1 2022 and bottomed at -$34.6 million in Q4 2022.
• The 5-year median for Consolidated Net Income is -$14.0 million (2023), against an average of -$5.2 million.
• Across the five-year window, Consolidated Net Income soared 8738.96% in 2022 and tumbled 1015.44% in 2025, its largest moves.
• Year by year, Consolidated Net Income stood at -$34.6 million in 2022, then advanced by 21.48% to -$27.1 million in 2023, then soared by 47.7% to -$14.2 million in 2024, then soared by 506.86% to $57.7 million in 2025, then plunged by 127.87% to -$16.1 million in 2026.
• Per Business Quant, the three latest QTTB Consolidated Net Income figures stand at -$16.1 million (Q1 2026), $57.7 million (Q4 2025), and -$7.4 million (Q3 2025).